相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Incidence, prevalence and mortality of bullous pemphigoid in England 1998-2017: a population-based cohort study
M. S. M. Persson et al.
BRITISH JOURNAL OF DERMATOLOGY (2021)
Dipeptidyl peptidase-4 inhibitors and bullous pemphigoid: A systematic review and adjusted meta-analysis
Kevin Phan et al.
AUSTRALASIAN JOURNAL OF DERMATOLOGY (2020)
Clinical and immunological characterization of 14 cases of dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid: a single-centre study
M. Hayashi et al.
BRITISH JOURNAL OF DERMATOLOGY (2020)
Increased risk of bullous pemphigoid in dipeptidyl peptidase 4 inhibitors: A nationwide, population-based, cohort study in Taiwan
Chih-Tsung Hung et al.
JOURNAL OF DERMATOLOGY (2020)
Bullous pemphigoid associated with the use of dipeptidil peptidase-4 inhibitors: analysis from studies based on pharmacovigilance databases
Juan A. Molina-Guarneros et al.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACY (2020)
Dipeptidyl-peptidaseIVinhibitors (DPP4i)-associated bullous pemphigoid: Estimating the clinical profile and exploring intraclass differences
Khalaf Kridin
DERMATOLOGIC THERAPY (2020)
Association Between Medication Use and Bullous Pemphigoid A Systematic Review and Meta-analysis
Sian-De Liu et al.
JAMA DERMATOLOGY (2020)
Evaluation of Risk of Bullous Pemphigoid With Initiation of Dipeptidyl Peptidase-4 Inhibitor vs Second-generation Sulfonylurea
Hemin Lee et al.
JAMA DERMATOLOGY (2020)
A Systematic Review of Drug-associated Bullous Pemphigoid
Matthew J. Verheyden et al.
ACTA DERMATO-VENEREOLOGICA (2020)
Dipeptidyl peptidase-4 inhibitors-associated bullous pemphigoid: A retrospective study of 168 pemphigoid and 9,304 diabetes mellitus patients
Yohei Kawaguchi et al.
JOURNAL OF DIABETES INVESTIGATION (2019)
Bullous pemphigoid
Denise Miyamoto et al.
ANAIS BRASILEIROS DE DERMATOLOGIA (2019)
Epitope-spreading phenomena in dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid
I. Garcia-Diez et al.
BRITISH JOURNAL OF DERMATOLOGY (2019)
Bullous pemphigoid with dipeptidyl peptidase-4 inhibitors: Clinical features and pathophysiology
Takaaki Murakami et al.
JOURNAL OF DIABETES INVESTIGATION (2019)
Dipeptidyl Peptidase 4 Inhibitors and the Risk of Bullous Pemphigoid Among Patients With Type 2 Diabetes
Antonios Douros et al.
DIABETES CARE (2019)
Japanese guidelines for the management of pemphigoid (including epidermolysis bullosa acquisita)
Hideyuki Ujiie et al.
JOURNAL OF DERMATOLOGY (2019)
Higher Frequency of Dipeptidyl Peptidase-4 Inhibitor Intake in Bullous Pemphigoid Patients than in the French General Population
Marthe Plaquevent et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2019)
Gliptin-associated Bullous Pemphigoid and the Expression of Dipeptidyl Peptidase-4/CD26 in Bullous Pemphigoid
Outi Lindgren et al.
ACTA DERMATO-VENEREOLOGICA (2019)
Subepidermal autoimmune bullous diseases: overview, epidemiology, and associations
Khalaf Kridin
IMMUNOLOGIC RESEARCH (2018)
Unique clinical and serological features of bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors
H. Horikawa et al.
BRITISH JOURNAL OF DERMATOLOGY (2018)
Dipeptidyl peptidase-4(DPP-4) inhibitors: promising new agents for autoimmune diabetes
Xia Wang et al.
CLINICAL AND EXPERIMENTAL MEDICINE (2018)
Bullous Pemphigoid and Dipeptidyl Peptidase 4 Inhibitors: A Disproportionality Analysis Based on the Japanese Adverse Drug Event Report Database
Masanori Arai et al.
DIABETES CARE (2018)
Bullous pemphigoid induced by dipeptidyl peptidase-4 inhibitors. Eight cases with clinical and immunological characterization
Irene Garcia-Diez et al.
INTERNATIONAL JOURNAL OF DERMATOLOGY (2018)
Decrease in eosinophils infiltrating into the skin of patients with dipeptidyl peptidase-4 inhibitor-related bullous pemphigoid
Chika Chijiwa et al.
JOURNAL OF DERMATOLOGY (2018)
Vildagliptin Significantly Increases the Risk of Bullous Pemphigoid: A Finnish Nationwide Registry Study
Outi Varpuluoma et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2018)
Oral diabetes medications other than dipeptidyl peptidase 4 inhibitors are not associated with bullous pemphigoid: A Finnish nationwide case-control study
Outi Varpuluoma et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2018)
Dipeptidyl peptidase IV inhibitors, a risk factor for bullous pemphigoid: Retrospective multicenter case-control study from France and Switzerland
Michael Benzaquen et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2018)
Humoral epitope Spreading in Autoimmune Bullous Diseases
Dario Didona et al.
FRONTIERS IN IMMUNOLOGY (2018)
Association of Bullous Pemphigoid With Dipeptidyl-Peptidase 4 Inhibitors in Patients With Diabetes Estimating the Risk of the New Agents and Characterizing the Patients
Khalaf Kridin et al.
JAMA DERMATOLOGY (2018)
Bullous autoimmune dermatoses
Silke C. Hofmann et al.
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT (2018)
Bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors: A report of five cases
Satoshi Yoshiji et al.
JOURNAL OF DIABETES INVESTIGATION (2018)
The Growing Incidence of Bullous Pemphigoid: Overview and Potential Explanations
Khalaf Kridin et al.
FRONTIERS IN MEDICINE (2018)
Use of Dipeptidyl-Peptidase IV Inhibitors and Bullous Pemphigoid
Clara Schaffer et al.
DERMATOLOGY (2017)
Incidence of bullous pemphigoid in Sweden 2005-2012: a nationwide population-based cohort study of 3761 patients
Kristofer Thorslund et al.
ARCHIVES OF DERMATOLOGICAL RESEARCH (2017)
The association between drugs and bullous pemphigoid
C. W. X. Tan et al.
BRITISH JOURNAL OF DERMATOLOGY (2017)
Bullous pemphigoid and dipeptidyl peptidase IV inhibitors: a case-noncase study in the French Pharmacovigilance Database
J. Bene et al.
BRITISH JOURNAL OF DERMATOLOGY (2016)
Three Cases of Bullous Pemphigoid Associated with Dipeptidyl Peptidase-4 Inhibitors-One due to Linagliptin
Francisco Manuel Ildefonso Mendonca et al.
DERMATOLOGY (2016)
Autoantibody Profile Differentiates between Inflammatory and Noninflammatory Bullous Pemphigoid
Kentaro Izumi et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2016)
Management of bullous pemphigoid: the European Dermatology Forum consensus in collaboration with the European Academy of Dermatology and Venereology
C. Feliciani et al.
BRITISH JOURNAL OF DERMATOLOGY (2015)
Bullous pemphigoid associated with dipeptidyl peptidase IV inhibitors. A case report and review of literature
Amy Attaway et al.
JOURNAL OF DERMATOLOGICAL CASE REPORTS (2014)
The Associations Between Bullous Pemphigoid and Drug Use A UK Case-Control Study
Antonia Lloyd-Lavery et al.
JAMA DERMATOLOGY (2013)
Drug-induced bullous pemphigoid in diabetes mellitus patients receiving dipeptidyl peptidase-IV inhibitors plus metformin
K. Skandalis et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2012)
Dipeptidyl Peptidase-4 Inhibitors Cause Bullous Pemphigoid in Diabetic Patients: Report of Two Cases
Efi Pasmatzi et al.
DIABETES CARE (2011)
Demonstration of Epitope-Spreading Phenomena in Bullous Pemphigoid: Results of a Prospective Multicenter Study
Giovanni Di Zenzo et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2011)
分享论文
